Vor Biopharma VOR Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$219.59M-576% | —— | -$812.68M-2,849% | -$1.57B-5,553% | -$32.49M-5.5% | ||
| $28K-96.6% | $23K-97.3% | $2K-99.8% | $2.1M+133% | $825K-12.5% | ||
| $8.87M+359% | $7.11M+316% | $8.03M+255% | $1.84M-34.0% | $1.93M-37.3% | ||
| -$0+100% | —— | —— | -$3.3M— | -$1K— | ||
| -$9.1M-563% | $6.21M+68.3% | $5M— | $1.1M— | -$1.37M+44.7% | ||
| $6.36M+2,653% | —— | —— | -$2.86M— | $231K-67.5% | ||
| -$61K+94.2% | -$59K+94.2% | -$20K+97.9% | -$1.28M-39.2% | -$1.05M-13.8% | ||
| -$38.25M-23.1% | -$22.8M+5.2% | -$53.66M-130% | -$35.18M-61.0% | -$31.07M-2.0% | ||
| $48K-79.2% | $314K+336% | $244K+618% | $152K+1,589% | $231K+103% | ||
| -$263.24M-114,351% | -$48.97M— | -$244K— | $646K-98.8% | -$230K-101% | ||
| $2K-96.4% | $148K+393% | $19K-72.9% | $32K-37.3% | $55K-69.8% | ||
| $74.87M+12,455% | $307.8M+478% | $21.55M+52,459% | $175.07M— | -$606K-731% | ||
| -$226.61M-610% | $236.02M+710% | —— | $140.53M+352% | -$31.9M-335% | ||
| $28K-96.6% | $23K-97.3% | $2K-99.8% | $2.1M+133% | $825K-12.5% | ||
| -$61K+94.2% | -$59K+94.2% | -$20K+97.9% | -$1.28M-39.2% | -$1.05M-13.8% | ||
| $20K+243% | $2.11M+1,739% | -$151K+72.6% | -$1.95M-11.0% | -$14K-300% | ||
| $6.36M+2,653% | —— | —— | -$2.86M— | $231K-67.5% | ||
| —— | $331.25K-43.0% | $331.25K-43.0% | $331.25K-43.0% | $331.25K-43.0% | ||
| $127K-77.0% | —— | $643K— | —— | $551K— | ||
| —— | $27.03M— | $27.03M— | $27.03M— | $27.03M— | ||
| $75M— | —— | —— | —— | $0-100% | ||
| $12K— | —— | —— | —— | $0-100% | ||
| $188.36M— | —— | $790.46M— | $1.3B— | $0— | ||
| -$61K+94.2% | -$59K+94.2% | -$20K+97.9% | -$1.28M-39.2% | -$1.05M-13.8% | ||
| $93K— | —— | —— | —— | $0— | ||
| —— | $44.34M— | $44.34M— | $44.34M— | $44.34M— | ||
| $109K-91.7% | $107K-91.7% | $60K-95.3% | $4.17M+233% | $1.31M+6.3% | ||
| -$38.29M-22.4% | -$23.12M+4.2% | -$53.91M-131% | -$35.34M-61.7% | -$31.3M-2.3% | ||
| -$38.29M-22.4% | -$23.12M+4.2% | -$53.91M-131% | -$35.34M-61.7% | -$31.3M-2.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Vor Biopharma generate?
- Vor Biopharma (VOR) generated -$149.9M in operating cash flow over the trailing twelve months.
- What is Vor Biopharma's free cash flow?
- After $758.0K of capital expenditures, Vor Biopharma's free cash flow was -$150.7M over the trailing twelve months, down 49.7% year over year.
- Where does Vor Biopharma's cash flow data come from?
- Every line is extracted from Vor Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.